ENDOTAK RELIANCE SG
Report
- Report Number
- 2124215-2023-58890
- Event Type
- Malfunction
- Date Received
- October 23, 2023
- Date of Event
- July 1, 2023
- Report Date
- February 21, 2024
- Manufacturer
- BOSTON SCIENTIFIC CORPORATION
- Product Code
- LWS
- PMA / PMN Number
- P910073/S043
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- OH, US
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
IF PERTINENT INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE SUBMITTED.
IF PERTINENT INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE SUBMITTED.
IT WAS REPORTED THAT THIS RIGHT VENTRICULAR (RV) LEAD EXHIBITED GRADUALLY INCREASING SHOCK IMPEDANCE MEASUREMENTS REACHING 150-155 OHMS FOR THE PAST FEW MONTHS. IT WAS NOTED THAT THE SHOCK IMPEDANCE MEASUREMENT AT IMPLANT WAS 64 OHMS. TECHNICAL SERVICES (TS) REVIEWED TROUBLESHOOTING OPTIONS AND POSSIBLE CAUSES. THIS RV LEAD REMAINS IN SERVICE. NO ADVERSE PATIENT EFFECTS WERE REPORTED. ADDITIONAL INFORMATION RECEIVED REPORTED THAT EXHIBITED ANOTHER HIGH OUT-OF-RANGE SHOCK IMPEDANCE MEASUREMENT OF 125 OHMS, WITH OTHER SHOCK IMPEDANC MEASUREMENTS AVERAGING IN THE 110-115 OHMS RANGE. TECHNICAL SERVICES (TS) REVIEWED TROUBLESHOOTING OPTIONS AND PROGRAMMING CONSIDERATIONS. THIS RV LEAD REMAINS IN SERVICE. NO ADVERSE PATIENT EFFECTS WERE REPORTED.
IT WAS REPORTED THAT THIS RIGHT VENTRICULAR (RV) LEAD EXHIBITED GRADUALLY INCREASING SHOCK IMPEDANCE MEASUREMENTS REACHING 150-155 OHMS FOR THE PAST FEW MONTHS. IT WAS NOTED THAT THE SHOCK IMPEDANCE MEASUREMENT AT IMPLANT WAS 64 OHMS. TECHNICAL SERVICES (TS) REVIEWED TROUBLESHOOTING OPTIONS AND POSSIBLE CAUSES. THIS RV LEAD REMAINS IN SERVICE. NO ADVERSE PATIENT EFFECTS WERE REPORTED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1852082 | ENDOTAK RELIANCE SG | IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (NON-CRT) | LWS | BOSTON SCIENTIFIC CORPORATION | 0180 | 302257 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 65 YR | Male |